SuperworthTectonic Therapeutic TECX
- Market cap
- $392.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −18.5%
Tectonic Therapeutic's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $8.1M−49% | $4.4M−76% | $10.8M−38% | $7.1M−19% | $14.3M+76% | $9.2M+109% | $13M+21% | $17.2M+143% | $16.9M+18% | $16.3M+79% | $20.9M+60% | $18M+5% |
| SG&A | $2M−72% | $5.2M−26% | $2.1M−73% | $4.3M+133% | $5.3M+169% | $4.8M−8% | $5.3M+145% | $5.1M+18% | $5M−7% | $5.2M+7% | $6.4M+22% | $6.2M+20% |
| −$10.1M−56% | −$9.7M−62% | −$13M−49% | −$11.4M+7% | −$19.6M+94% | −$14M+45% | −$18.3M+41% | −$22.3M+96% | −$21.9M+12% | −$21.5M+54% | −$27.3M+49% | −$24.2M+8% | |
| Interest expense | $36K−93% | $34K−94% | $31K−94% | $28K−30% | $25K−31% | $22K−35% | $20K−36% | $17K−39% | $14K−44% | $12K−46% | $8K−60% | $6K−65% |
| Pre-tax income | n/a | n/a | n/a | −$12.7M | −$17.7M | −$12.4M | n/a | −$19M+50% | −$19M+7% | −$19M+53% | n/a | −$22.2M+17% |
| n/a | n/a | n/a | $0 | $0 | $0 | n/a | $976K | $0 | $254K | n/a | $77K−92% | |
| Net income | −$10.1M−56% | −$8.8M−65% | −$15.2M−39% | −$12.7M+21% | −$17.7M+76% | −$12.4M+41% | −$15.9M+5% | −$20M+58% | −$19M+7% | −$19.2M+55% | −$25.2M+59% | −$22.3M+12% |
| −$7.62+22% | −$2.40−65% | −$10.97+60% | −$4.34−49% | −$1.20−84% | −$0.84−65% | −$0.93−92% | −$1.07−75% | −$1.02−15% | −$1.03+23% | −$1.34+44% | −$1.18+10% | |
| 1.3M−64% | 1.3M−63% | 1.4M−62% | 2.9M+138% | 14.7M+1017% | 14.8M+1007% | 17.2M+1137% | 18.7M+540% | 18.7M+27% | 18.7M+27% | 18.8M+9% | 19M+2% |
R&D: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
SG&A: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Operating income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Net income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
EPS, diluted: 11 periods, Q1 FY17 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY17: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY17 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Tectonic Therapeutic's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TECXTectonic Therapeutic | $392.4M | n/m | 2.2× | n/m | n/m | n/m | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| Peer median | $1.5B | 14.1× | 27.8× | 3.6× | +23% | 21.7% |
More on Tectonic Therapeutic
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .